Adjuvant antibody therapy with trastuzumab in early breast cancer

被引：0
|
作者：
Untch, Michael
Scharl, Anton
Jackisch, Christian
Thomssen, Christoph
Nitz, Ulrike
von Minckwitz, Gunter
Harbeck, Nadia
机构：
[1] Univ Charite, Akad LK, Helios Klinikum Berlin Buch, Frauenklin,Interdisziplinaires Brustzentrum, D-13125 Berlin, Germany
[2] Frauenklin Amberg, Amberg, Germany
[3] Frauenklin Offenbach, Offenbach, Germany
[4] Univ Halle Wittenberg, Frauenklin, D-4010 Halle, Germany
[5] Univ Dusseldorf, Frauenklin, D-4000 Dusseldorf, Germany
[6] GBG Forsch GmbH, Neu Isenburg, Germany
[7] Tech Univ Munich, Frauenklin, D-8000 Munich, Germany
来源：
BREAST CARE | 2006年 / 1卷 / 04期
关键词：
HER2/neu; monoclonal antibody; breast cancer; trastuzumab; adjuvant therapy;
D O I：
10.1159/000094891
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy with the monoclonal antibody trastuzumab is a well established cornerstone of an individualized treatment strategy for women with HER2/neu-over-expressing breast cancer. Based on the reported data of clinical studies comprising more than 14,000 women, trastuzumab was approved throughout the European Union in May 2006 for adjuvant therapy in patients with early-stage HER2/neu-overexpressing breast cancer.
引用
收藏
页码：252 / 255
页数：4
相关论文
共 50 条
  • [21] Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer
    Bellon, JR
    Gover, MT
    Burstein, HJ
    Harris, JR
    Harris, LN
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S55 - S56
  • [22] Adjuvant hormonal therapy in early breast cancer
    Kumar, Satish
    Leonard, R. C. F.
    [J]. ONCOLOGY-NEW YORK, 2005, 19 (11): : 1425 - +
  • [23] Adjuvant therapy for early stage breast cancer
    Sledge, GW
    [J]. SEMINARS IN ONCOLOGY, 1996, 23 (01) : 51 - 54
  • [24] Adjuvant Targeted Therapy in Early Breast Cancer
    Mackey, John
    McLeod, Deanna
    Ragaz, Joseph
    Gelmon, Karen
    Verma, Sunil
    Pritchard, Kathleen
    Laing, Kara
    Provencher, Louise
    Charbonneau, Lauren F.
    [J]. CANCER, 2009, 115 (06) : 1154 - 1168
  • [25] Adjuvant endocrine therapy for early breast cancer
    Andreetta, Claudia
    Smith, Ian
    [J]. CANCER LETTERS, 2007, 251 (01) : 17 - 27
  • [26] ADJUVANT THERAPY IN EARLY BREAST-CANCER
    CHITTOOR, SR
    SWAIN, SM
    [J]. AMERICAN FAMILY PHYSICIAN, 1991, 44 (02) : 453 - 462
  • [27] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    [J]. ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [28] Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer
    Ishihara, Mikiya
    Mukai, Hirofumi
    Nagai, Shunji
    Mukohara, Toru
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (05) : 431 - 435
  • [29] Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer - A lifetime model
    Millar, J. Alasdair
    Millward, Michael J.
    [J]. PHARMACOECONOMICS, 2007, 25 (05) : 429 - 442
  • [30] Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer
    Fagnani, Francis
    Colin, Xavier
    Arveux, Patrick
    Coudert, Bruno
    Misset, Jean-Louis
    [J]. BULLETIN DU CANCER, 2007, 94 (7-8) : 711 - 720
12345